Published in
Springer Nature [academic journals on nature.com], British Journal of Cancer, 1(119), p. 27-35, 2018
DOI: 10.1038/s41416-018-0132-8
Links
- ORCID
- Springer Nature [academic journals on nature.com] | PDF
- [hdl.handle.net]
- [discovery.ucl.ac.uk] | PDF
- [eprints.nottingham.ac.uk] | PDF
Tools
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial.
Journal article published in 2018 by
Alison C. Backen,
Andre Lopes,
Harpreet Wasan,
Daniel H. Palmer,
Marian Duggan,
David Cunningham 
,
Alan Anthoney,
Pippa G. Corrie,
Srinivasan Madhusudan,
Anthony Maraveyas,
Paul J. Ross,
Justin S. Waters,
William P. Steward,
Charlotte Rees,
Mairéad G. McNamara
and other authors.
,
Alan Anthoney,
Pippa G. Corrie,
Srinivasan Madhusudan,
Anthony Maraveyas,
Paul J. Ross,
Justin S. Waters,
William P. Steward,
Charlotte Rees,
Mairéad G. McNamara
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
Advanced biliary tract cancer (ABC) has a poor prognosis. Cediranib, in addition to cisplatin/gemcitabine [CisGem], improved the response rate, but did not improve the progression-free survival (PFS) in the ABC-03 study. Minimally invasive biomarkers predictive of cediranib benefit may improve patient outcomes.